| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 169,647 | 117,324 | ||
| Short-term investments | 321,254 | 446,032 | ||
| Unbilled revenue | 70,000 | - | ||
| Prepaid expenses and other current assets | 11,012 | 15,394 | ||
| Total current assets | 571,913 | 578,750 | ||
| Property and equipment, net | 1,125 | 1,091 | ||
| Operating lease right-of-use asset | 2,582 | 1,977 | ||
| Other assets | 1,518 | 506 | ||
| Total assets | 577,138 | 582,324 | ||
| Current portion of long-term debt | - | 8,435 | ||
| Current portion of deferred revenue - related party | - | 288 | ||
| Accounts payable | 10,063 | 8,518 | ||
| Accrued liabilities | 40,633 | 35,344 | ||
| Total current liabilities | 50,696 | 52,585 | ||
| Long-term debt | 20,890 | 12,353 | ||
| Other liabilities | 2,582 | 2,077 | ||
| Deferred revenue - related party | - | 140 | ||
| Total liabilities | 74,168 | 67,155 | ||
| Preferred stock-Series APreferred Stock | 61,188 | 61,188 | ||
| Preferred stock-Series BPreferred Stock | 127,697 | 127,697 | ||
| Common stock, 0.01 par value 200,000,000 shares authorized 82,229,158 and 80,994,046 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 822 | 817 | ||
| Additional paid-in capital | 1,531,003 | 1,508,902 | ||
| Accumulated other comprehensive income (loss) | 363 | 69 | ||
| Accumulated deficit | -1,218,103 | -1,183,504 | ||
| Total stockholders equity | 502,970 | 515,169 | ||
| Total liabilities and stockholders equity | 577,138 | 582,324 | ||
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)